将痛风指南建议纳入尿酸报告与住院率降低相关:一项观察性研究
该观察性研究评估了在NHS Lothian地区将痛风治疗指导(尿酸目标值)纳入尿酸检测报告后的影响。结果显示,与苏格兰其他卫生委员会相比,Lothian地区以痛风为主要诊断和次要诊断的住院率均显著降低,但主要诊断的本地年入院数变化无统计学意义。别嘌醇300mg片剂和非布司他120mg片剂处方率的相对增加可能有助于改善结局。
要点
- 将痛风指南建议纳入尿酸报告与痛风相关住院率相对降低相关。
- Lothian地区痛风次要诊断住院数显著减少(58/年 vs 39/年,P<0.01)。
- 其他苏格兰地区痛风住院率同期显著上升,形成对比。
核心结论
- 将临床指南建议纳入常规尿酸结果报告与NHS Lothian地区痛风住院率降低相关,与其他苏格兰卫生委员会相比差异显著。
研究设计与样本
- 观察性研究,分析2009至2020年苏格兰全区降尿酸治疗处方和痛风住院数据,以及2014至2015年Lothian地区尿酸检测数据;干预为2014年9月后对临床确诊痛风且尿酸>0.36 mmol/l的结果添加尿酸目标值。
主要发现
- Lothian地区痛风主要诊断年入院数从2010-2014年的111/年降至2015-2019年的104/年,差异无统计学意义(P=0.32)。
- 同期苏格兰其他卫生委员会痛风主要诊断入院数从556/年显著增至606/年(P<0.01)。
- Lothian地区痛风次要诊断入院数从58/年显著降至39/年(P<0.01),其他苏格兰卫生委员会从220/年显著增至290/年(P<0.01)。
- 以2009年为基线,干预后Lothian地区相对于其他苏格兰卫生委员会的入院相对率显著降低:主要诊断痛风为1.06 vs 1.25(P<0.001),次要诊断痛风为0.64 vs 1.4(P<0.001);干预前无差异。
- 别嘌醇300mg片剂和非布司他120mg片剂处方率的相对增加可能 contributed 于观察到的结局改善。
关键数值与推荐
- 纳入报告的尿酸阈值为>0.36 mmol/l。
- 干预对象为临床确诊痛风且尿酸结果>0.36 mmol/l的检测。
临床怎么用
- 在尿酸检测报告中嵌入痛风治疗目标值和指南建议可能有助于降低痛风相关住院风险。
- 关注降尿酸药物如别嘌醇300mg和非布司他120mg的处方率变化可能对结局有影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the impact of incorporating treatment guidance into reporting of urate test results. METHODS: Urate targets for clinically confirmed gout were added to urate results above 0.36 mmol/l requested after September 2014 within NHS Lothian. Scotland-wide data on urate-lowering therapy prescriptions and hospital admissions with gout were analysed between 2009 and 2020. Local data on urate tests were analysed between 2014 and 2015. RESULTS: Admissions with a primary diagnosis of gout in Lothian reduced modestly following the intervention from 111/year in 2010-2014 to 104/year in 2015-2019, a non-significant difference (P = 0.32). In contrast there was a significant increase in admissions to remaining NHS Scotland health boards (556/year vs 606/year, P < 0.01). For a secondary diagnosis of gout the number of admissions in NHS Lothian reduced significantly (58/year vs 39/year, P < 0.01) contrasting with a significant increase in remaining Scottish health boards (220/year vs 290/year, P < 0.01). The relative rate of admissions to NHS Lothian compared with remaining Scottish boards using a 2009 baseline were significantly reduced for both primary diagnosis of gout (1.06 vs 1.25, P < 0.001) and secondary diagnoses of gout (0.64 compared with 1.4, P < 0.001) after the intervention; however, there was no difference before the intervention. A relative increase in the prescription rates of allopurinol 300 mg tablets and febuxostat 120 mg tablets may have contributed to the improved outcomes seen. CONCLUSION: Incorporation of clinical guideline advice into routine reporting of urate results was associated with reduced rates of admission with gout in NHS Lothian, in comparison with other Scottish health boards.
引用
- Riches PL, Downie L, Thomson C, et al. Incorporating gout guideline advice into urate reports is associated with reduced hospital admissions: results of an observational study. Rheumatology (Oxford). 2022. PMID: 34528071. doi:10.1093/rheumatology/keab689
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。